MGTX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

MG

Mkt Cap

$891.2M

Volume

544.59K

Next Earnings

November 12th

Loading chart

MG

MGTXMeiraGTx Holdings plc Ordinary Shares

MGTX

Pay with—

Available Balance0.00

MG

Mkt Cap

$949.9M

Volume

544.59K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

What This MeiraGTx Insider Sale Might Mean With Two Drug Filings NearMeiraGTx Chief Scientific Officer Stuart Naylor sold 27,659 shares (4% of holdings) for $409,000 on July 7, 2026, under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025. The sale appears routine following an 89% one-year stock surge and likely reflects portfolio diversification rather than lack of confidence. The company remains well-positioned with a Lilly collaboration worth $75M upfront plus $400M+ in milestones, FDA Breakthrough Therapy Designation for its dry-mouth therapy, and plans to file for approval on two wholly-owned therapies within two years.The Motley Fool · Jul 12, 2026

Eli Lilly Partner MeiraGTx Regains Rights For Genetic Eye Disease Drug From Johnson & JohnsonMeiraGTx reacquired bota-vec, a treatment for X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson for a $25 million upfront payment. The company raised $100 million through a share offering and plans to expedite regulatory filings for U.S. and EU approval with a potential 2027 launch. Three-year data from its xerostomia treatment showed durable benefits. Stock declined 15.8% on the announcement.Benzinga · Apr 16, 2026

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)MeiraGTx has entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in botaretigene sparoparvovec (bota-vec) for treating X-linked retinitis pigmentosa. The company will pay $25 million upfront plus regulatory and commercial milestones, with royalties on global net sales. Phase 3 LUMEOS study data showed clinically meaningful improvements across multiple vision domains, with 45% of treated patients gaining >10 letters in low luminance visual acuity. MeiraGTx intends to file for regulatory approval in the U.S., EU, and Japan with a potential launch in 2027.Benzinga · Apr 16, 2026

Eli Lilly Expands Genetic Eye-Disease Focused Pipeline With MeiraGTx Gene Therapy CollaborationEli Lilly signed a strategic collaboration with MeiraGTx for ophthalmology gene therapy, granting worldwide exclusive rights to AAV-AIPL1 program for Leber congenital amaurosis 4, with an upfront payment of $75 million and potential milestone payments over $400 million.Benzinga · Nov 10, 2025

MeiraGTx Sales Jump 1,133 PercentMeiraGTx reported Q2 2025 results with significant revenue growth but missed analyst estimates. The company advanced several gene therapy programs, secured key partnerships, and maintained strong manufacturing capabilities despite ongoing financial challenges.The Motley Fool · Aug 14, 2025

AAV for the Hereditary Retinal Diseases Clinical Trial Pipeline Analysis Demonstrates 70+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsightA comprehensive analysis reveals over 70 companies developing AAV gene therapies for hereditary retinal diseases, offering potential transformative treatments for vision restoration through advanced gene therapy techniques.GlobeNewswire Inc. · Aug 5, 2025

Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS DiseasesCoave Therapeutics, a company pioneering genetic medicines, has established a new Scientific Advisory Board (SAB) with renowned experts in AAV vector biology, gene therapy for ophthalmology and CNS diseases, and extra-hepatic gene delivery. The SAB will provide strategic guidance to support Coave's R&D initiatives and the development of its ALIGATER platform.GlobeNewswire Inc. · May 21, 2025

Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsightThe Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.GlobeNewswire Inc. · Apr 22, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ CompaniesThe report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safety, specificity, and efficiency.GlobeNewswire Inc. · Mar 4, 2025

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Misses Revenue EstimatesCRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of 12.27% and 93.94%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?Zacks Investment Research · May 8, 2024

to start trading

MG

MGTXMeiraGTx Holdings plc Ordinary Shares

MGTX

Pay with—

Available Balance0.00

Your PositionYou don't own any MGTX yet.

Related Tickers

Earnings